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Abstract
Type 1 Epstein-Barr virus (EBV) strains immortalize B lymphocytes in vitro much more efficiently than type 2 EBV, a difference
previously mapped to the EBNA-2 locus. Here we demonstrate that the greater transforming activity of type 1 EBV correlates
with a stronger and more rapid induction of the viral oncogene LMP-1 and the cell gene CXCR7 (which are both required for
proliferation of EBV-LCLs) during infection of primary B cells with recombinant viruses. Surprisingly, although the major
sequence differences between type 1 and type 2 EBNA-2 lie in N-terminal parts of the protein, the superior ability of type 1
EBNA-2 to induce proliferation of EBV-infected lymphoblasts is mostly determined by the C-terminus of EBNA-2.
Substitution of the C-terminus of type 1 EBNA-2 into the type 2 protein is sufficient to confer a type 1 growth phenotype
and type 1 expression levels of LMP-1 and CXCR7 in an EREB2.5 cell growth assay. Within this region, the RG, CR7 and TAD
domains are the minimum type 1 sequences required. Sequencing the C-terminus of EBNA-2 from additional EBV isolates
showed high sequence identity within type 1 isolates or within type 2 isolates, indicating that the functional differences
mapped are typical of EBV type sequences. The results indicate that the C-terminus of EBNA-2 accounts for the greater
ability of type 1 EBV to promote B cell proliferation, through mechanisms that include higher induction of genes (LMP-1 and
CXCR7) required for proliferation and survival of EBV-LCLs.
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Introduction
Epstein-Barr Virus (EBV) is a B-lymphotropic gamma herpesvi-
rus which persistently infects over 90% of the adult population
world-wide. EBV infection is usually asymptomatic, although in
some cases the virus can be the causative agent of infectious
mononucleosis[1].EBV isalsoinvolvedinsome B cellcancers,such
as Burkitt’s Lymphoma (BL), Hodgkin’s Lymphoma and lympho-
proliferative disease in immunocompromised hosts, in addition to
various epithelial tumors, for example nasopharyngeal carcinoma
(NPC) and gastric cancer [2]. In vitro, EBV can efficiently immor-
talize primary B cells, converting them into permanently growing
lymphoblastoid cell lines (LCLs), in which the viral genome is
maintained in an episomal form. A specific viral gene expression
program, known as latency III [3], is activated in LCLs and this
involves expression of six nuclear antigens (EBNA-1, -2, -3A, -3B, -
3C and -LP), three membrane proteins (LMP-1, -2A and -2B), and
various non-coding small RNAs (EBERs and miRNAs). Together
these viral gene products activate the resting B cells and sustain their
continuous proliferation. [1]. Work with recombinant EBV viruses
has demonstrated that at least five of the latent proteins (EBNA-1, -
2, -3A, -3C and LMP-1) are essential for EBV-mediated B cell
transformation, while EBNA-LP and LMP-2 can contribute to
optimal efficiency of this process [4-11].
EBV isolates can be classified as type 1 or type 2 (also known as
type A and B) based on linked sequence variation in the latent
genes EBNA-2, EBNA-3A, -3B, -3C and EBNA-LP. The most
divergent locus between the two viral types is EBNA-2, which
defines the viral types. There is about 50% difference in the
predicted primary amino acid sequence, which is strikingly high if
compared to the extremely low degree of variation in the rest of
the EBV genome [12–17]. Type 1 strains of EBV are ubiquitous in
the world, whereas type 2 strains are frequent in some areas of
Central Africa and some other parts of the world where malaria is
endemic. In these regions, type 1 and type 2 EBV have
approximately equal prevalence [18]. The major biological
difference between the two viral types is that type 1 EBV
immortalizes B cells in vitro much more efficiently than type 2 EBV
[19]. Experiments with a recombinant type 2 EBV virus carrying a
type 1 EBNA-2 sequence showed that this virus gained a type 1
immortalization phenotype, demonstrating that the difference in
transformation efficiency is determined by the EBNA-2 locus [5].
The in vitro transforming activities of type 1 and type 2 EBV also
correlate with the frequency of tumor formation in SCID mice
inoculated with type 1 or type 2 EBV in vitro-transformed LCLs
[20,21]. Despite the clear difference in growth phenotype in vitro,
there is so far no obvious disease association or in vivo phenotype
known for type 1 and type 2 EBV strains, although one study
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cause infectious mononucleosis, compared to type 2 strains [22].
Upon EBV infection of naı ¨ve B cells in vitro, EBNA-2 and EBNA-
LP are the first viral latent proteins expressed. EBNA-2 is a
transcription factor that can activate expression of the viral Cp and
LMP promoters and many cell genes crucial for B cell survival and
proliferation [1,23–26]. Activation of some of these promoters by
EBNA-2 is enhanced by cooperation with EBNA-LP [27-31].
Sequencecomparison analysisofthe EBNA-2allelefromtype1 and
type 2 EBV and different primate lymphocryptoviruses, led to
identification of nine evolutionary conserved regions (CR1 to CR9)
which represent much of the total sequence homology between type
1 and type 2 EBNA-2 proteins and define some functional domains
and important structures of the protein [13,32] (see diagram below).
CRs 1 to 4 at the N-terminus of the protein correspond to two self-
association domains [33,34] and a poly-proline region, which
consists of a variable number of consecutive proline residues,
depending on the virus strain. CRs 5 to 9 are located in the C-
terminal half of theEBNA-2protein, separated fromthe N-terminal
cluster of CRs by the diversity region, where the sequence similarity
between type 1 and type 2 EBNA-2 is very low. CR5 is involved in
association with the host DNA-binding protein RBP-Jk and CR6
mediates the interaction withthe cell protein SKIP, which facilitates
EBNA-2/RBP-Jk complex formation [35,36]. CR8 is part of an
acidic transactivation domain (TAD), which mediates gene
transcriptional activation, whereas CR9 coincides with a nuclear
localization signal (NLS). An additional karyophilic signal is
represented by the RG sequence, which consists of an 18-amino
acid stretch rich in arginines and glycines [32]. Four domains of
EBNA-2 have been shown to be involved in EBNA-2/EBNA-LP
cooperation: the TAD, amino acids 1 to 58, the RG motif and the
CR7 [31,37]. Detailed mutational analysis of the type 1 EBNA-2
protein led to mapping the regions essential for transformation.
These regions are mostly also essential for transactivation of the
LMP-1 promoter, suggesting that transformation and transactiva-
tion functions of EBNA-2 are closely related [38]. In the N-terminal
half of EBNA-2,residues3 to 30havebeenshown to be required for
induction of LMP-1 expression and, consequently, for immortali-
zation maintenance, using the EREB2.5 trans-complementation
system [39]. CR4 has been shown to contribute to EBNA-2
mediated immortalization of B cells, as mutant viruses with a
deleted CR4 are drastically impaired in B cell transformation [40].
B cellinfectionexperimentswith recombinant viruses suggested that
a minimum of seven prolines in the poly-proline region is required
for transformation, whereas in the EREB2.5 trans-complementation
assay, the whole poly-proline region was found to be dispensable for
EBNA-2-mediated immortalization maintenance [41,42]. In the C-
terminal half of the protein, the transactivation domain and the
RBP-Jk-binding region are absolutely required for B cell immor-
talization and LMP-1 induction [38,43]. The RG motif has been
demonstrated to be important for optimal B lymphocyte transfor-
mation efficiency [44]. However, a deletion mutant EBNA-2
protein lacking the RG sequence displayed a four-fold increase in
the activation of the LMP-1 promoter in reporter assays, compared
to wild-type EBNA-2, suggesting that the RG domain is a negative
regulator of EBNA-2 activity on the LMP-1 promoter [44].
EBNA-2 mechanisms of transcriptional activation have been
identified by many studies, which have mainly involved type 1
EBNA-2, whereas less is known about the type 2 EBNA-2. EBNA-
2 does not bind directly to DNA but is tethered to EBNA-2
responsive promoters by interacting with various cell DNA-bound
transcription factors. For example, it interacts through its
conserved WWPP motif with the transcriptional repressor RBP-
Jk (CBF1), thereby converting RBP-Jk to the transcriptionally
active form [35,45]. Additional cell sequence-specific transcription
factors are involved in EBNA-2 recruitment at some target
promoters, such as Spi-1/PU.1, AP-2 and AUF1 [46–50]. EBNA-
2-mediated gene transcription is activated by the transactivation
domain which interacts with several cell basal transcription factors
(TFIIH, TAF40, TFIIB and p100/TFIIE) and histone acetyl-
transferases (p300/CBP and PCAF) [51–54]. Other EBNA-2-
interacting partners are involved in chromatin remodelling, such
as proteins of the cell SWI-SNF complex [55,56].
EBNA-LP contains multiple copies of an N-terminal 66-aa
domain encoded by two exons (W1 and W2), located within each
of the BamHI W repeats of the EBV genome, and a unique C-
terminal 45-aa domain encoded by the Y1 and Y2 exons within
the downstream BamHI Y fragment [57–59]. Due to variations in
the number of BamHI W repeats in different viruses and
alternative splicing between the repeated W1W2 exons and the
unique Y1Y2 exons, EBNA-LP proteins of different sizes can be
expressed in EBV-infected cells. Genetic studies showed that
recombinant viruses lacking the C-terminal 45 amino acids display
a markedly lower immortalization efficiency compared to wild-
type viruses and require feeder cells, suggesting that EBNA-LP is
important but not essential for EBV-induced immortalization
[6,9]. Importantly, EBNA-LP has been shown to cooperate with
EBNA-2 and enhance EBNA-2 transcriptional activation of both
viral (LMP-1/LMP-2B, Cp) and cell (cyclin D2) target promoters
[27–31]. Most of the cooperative function of EBNA-LP maps to
the W1W2 repeats, whereas the unique carboxyl-terminal Y1Y2
domains modulate EBNA-LP function [28,29]. Only proteins with
2 or more copies of the W1W2 repeat are capable of cooperating
with EBNA-2 and viruses with two BamHI W repeats are
immortalization-competent [17,29,60,61].
LMP-1 is required for establishment of B cell transformation in
vitro [8] and is also required for continuous proliferation of EBV-
infected LCLs [62]. Regulation of LMP-1 by EBNA-2 is complex
and involves many cell proteins, including RBP-Jk, PU.1, AP-2,
SWI-SNF, CBP/p300, ATF/CREB [46-49,54,63]. Unlike other
EBNA-2 target promoters (e.g. LMP-2A), the EBNA-2/RBP-Jk
interaction plays only a minor role in EBNA-2-induced activation
of the LMP-1 promoter [64]. Since the EBNA-2 domains that are
essential for B cell transformation and LMP-1 induction are
Author Summary
Epstein-Barr virus (EBV) is a common human virus that is
involved in several types of cancer and directly causes
human B lymphocytes to proliferate when they become
infected. EBV occurs naturally as two different viral types
(type 1 and type 2). The genomes of these viruses are
mostly very similar but they differ in a few genes,
particularly the EBNA-2 gene. For many years it has been
known that type 1 EBV is much more effective than type 2
EBV at causing B lymphocyte proliferation and this
difference is mediated by the EBNA-2 gene. Here we have
shown that the greater ability of type 1 EBNA-2 to cause B
cell proliferation is due to superior induction of the EBV
LMP-1 and the cell CXCR7 genes, both of which are
required for growth of EBV-infected lymphocytes. We
mapped the section of type 1 EBNA-2 responsible for this
to the C-terminus of the protein, including the transactiva-
tion and EBNA-LP interaction domains. The results provide
a mechanism for the long-standing question of the
functional difference between these two major types of
EBV and will be important in understanding the signifi-
cance of the EBV types in human infection.
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a key role in EBNA-2-induced B lymphocyte transformation [65].
Several studies have used microarray analysis to identify human
genes that are targets of type 1 EBNA-2 [23–25] but until recently
little was known about the ability of type 2 EBNA-2 to regulate gene
expression. In earlier reports the abilities of type 1 and type 2 EBNA-
2 to up-regulate gene expression were compared only on two
individual promoters, LMP-1 and CD23 [66,67]. Recently we
compared the host genes induced by type1 EBNA-2 to those induced
by the type 2. Only a few genes were found to be differentially
regulated (CXCR7, MARCKS, IL1b and ADAMDEC), with a
stronger induction by type 1 EBNA-2 [26]. Among these, CXCR7
was the most differentially regulated gene and was also shown to be
required for proliferation of EBV-infected LCLs. Expression of
MARCKS, IL1b a n dA D A M D E Cw a sv e r yl o wi nL C L sa n dm a y
not be significant [26]. CXCR7 (RDC1, CMKOR1) is a G-protein
coupled chemokine receptor with seven trans-membrane domains
[68,69]. CXCR7 binds with high affinity to the inflammatory and
homing chemokines CXCL12/SDF-1 and CXCL11/ITAC, which
are also ligands for CXCR4 and CXCR3 respectively [70,71].
CXCR7 is believed to be an atypical chemokine receptor since
neither coupling of the receptor to G-proteins nor CXCR7-mediated
triggering of typical chemokine responses, such as chemotaxis or
receptor-induced calcium mobilization, could be demonstrated [70-
73]. Therefore, CXCR7 has been proposed to be mainly a
modulator of CXCR4 and CXCR3 signalling, possibly acting as a
‘‘decoy’’ receptor to scavenge and sequester CXCL12/SDF-1 and
CXCL11/ITAC [74,75]. This is suggested by the observation that
CXCR7 expression on mature B cells inversely correlates with the
activity of CXCR4 [76]. Alternatively, a function for CXCR7 as co-
receptor for CXCR4 has also been proposed, as the two receptors
can heterodimerize [77]. Analysis of CXCR7 expression in normal
human leukocytes revealed that the mRNA is broadly expressed in
variousfractionsofrestingPBMCs,includingBcells[76,78],whereas
the protein seems to be strictly expressed at the plasma membrane of
monocytes and B cells [76]. However, surface CXCR7 was not
consistently detected on B cells in another study [78]. CXCR7 has
been implicated in tumorigenesis based on the observation that
ectopic expression of the gene induces tumor formation in nude mice
[79]. Moreover, CXCR7 protein has been shown to be expressed on
many human and mouse tumor cell lines and to confer a strong
growth and survival advantage to the cells [71,80–82].
In this study we show that LMP-1 and CXCR7 mRNAs are
differentially induced by type 1 and type 2 EBV during the early
stages of infection of primary B cells with recombinant EBV
viruses, consistent with differential induction of these genes being
the basis for the weaker ability of type 2 EBV strains to transform
primary B cells. EBNA-2 type, rather than the type of EBNA-LP,
is shown to be the major determinant of the differential induction
of LMP-1 oncoprotein and the C-terminal region of EBNA-2 is
responsible for the superior ability of the type 1 protein to
maintain proliferation of B cells. Within this region, the RG, CR7
and TAD are the minimum type 1 domains required for type 1
growth phenotype and sufficient LMP-1/CXCR7 expression
levels. The results demonstrate a mechanism for the enhanced
capability of type 1 strains of EBV to transform B cells into LCLs.
Results
Differential regulation of LMP-1 and CXCR7 mRNA by ER-EBNA-
2 shows that type 1 EBNA-2 induces LMP-1 and CXCR7 to a
higher level and more rapidly than type 2 EBNA-2
We previously identified CXCR7 as the most differentially
regulated type-specific EBNA-2-target gene in the human genome,
being more strongly induced by type 1 EBNA-2 in a BL cell
background [26]. RNAi experiments demonstrated that CXCR7
is required for proliferation of EBV-LCLs [26]. We also showed, in
an EBV-positive BL cell line with oestrogen-regulated EBNA-2
proteins, that type 1 EBNA-2 induced LMP-1 protein more
rapidly and to a higher extent compared to the type 2 [26]. This
has been now verified at the RNA level using the same system.
Briefly, this consists of Daudi cells (which lack the EBNA-2 locus
[83] and therefore expression of LMP-1) engineered to stably
express type 1 or type 2 chimaeric EBNA-2 proteins fused to the
hormone-binding domain of the oestrogen receptor (ER-EBNA-2)
[26]. In the absence of oestrogen, the ER-tagged EBNA-2 proteins
are localized to the cytoplasm and therefore inactive [84].
Addition of oestrogen results in normal localization of the
EBNA-2 fusion proteins to the nucleus and therefore in activation
of the LMP-1 gene from the resident EBV genome. In a time-
course experiment of oestrogen stimulation over 48 hours, total
cell RNA from the cell lines containing type 1 or type 2 ER-
EBNA-2 was analyzed by ribonuclease protection assay (RPA)
using an LMP-1 specific probe (Figure 1 A). When type 1 EBNA-2
function was activated, LMP-1 mRNA levels were strongly
induced as soon as 8 hours after the stimulation and were
maintained thereafter throughout the time-course. In contrast,
after induction of type 2 EBNA-2 function, markedly lower levels
of LMP-1 transcripts were detected. Analysis by qRT-PCR for
LMP-1 mRNA gave a similar result (Figure 1 B) and qRT-PCR
analysis was also performed for CXCR7 transcripts levels in the
same experiment (Figure 1 C). These were found to be
significantly higher in type 1 EBNA-2 cell lines stimulated with
oestrogen than in type 2 cells that had undergone the same
treatment. Agarose-gel electrophoresis analysis of total cell RNA
used for the RPA analysis confirmed equal loading and no
degradation of the samples (data not shown). The somewhat
higher expression of type 2 ER-EBNA-2 in the Daudi cell line
(Figure S1 and [26]) further emphasizes the superior induction of
target genes by type 1 ER-EBNA-2.
The more rapid induction of LMP-1 by type 1 EBNA-2 was also
confirmed in the type 2 EBV P3HR1 cl.16 BL cell line. The
resident EBV genome in P3HR1 cl.16 line also lacks the EBNA-2
locus and the Y1Y2-coding region of EBNA-LP, having a deletion
similar but not identical to that present in Daudi cells [83,85].
Plasmids expressing type 1 or type 2 ER-EBNA-2 (p554-4 and its
type 2 derivative, described in Materials and Methods and in
[26,86]) were transfected into P3HR1 cl.16 cells and stable cell
lines were selected with G418. In P3HR1 cl.16 cells, despite the
absence of EBNA-2, basal expression of LMP-1 can still be
detected, albeit at very low levels (Figure 1 D). Nevertheless, when
a time-course experiment of oestrogen stimulation was performed,
a clear increase of LMP-1 expression levels above background was
detected by western blotting when type 1 EBNA-2 function was
activated (Figure 1 D). LMP-1 induction was detected as soon as 4
hours after oestrogen stimulation; after 8 hours LMP-1 expression
level reached its maximum and was thereafter maintained
throughout the time-course. Conversely, when type 2 EBNA-2
function was activated by oestrogen, LMP-1 levels were induced
only moderately above the background, with a modest peak at
20 hours followed by a slight decrease (Figure 1 D).
Weaker induction of LMP-1 by type 2 EBNA-2 is not
affected by the EBNA-LP type
As EBNA-LP is important in cooperation with EBNA-2 for
induction of LMP-1 [28,29], we determined which isoforms of
EBNA-LP are expressed in normal Daudi and P3HR1 cl.16 cells
and in the derivative stable cell lines bearing the oestrogen-
EBNA-2 Type Specific Regulation of LMP-1 and CXCR7
PLoS Pathogens | www.plospathogens.org 3 July 2011 | Volume 7 | Issue 7 | e1002164inducible EBNA-2 proteins (Figures S1 and S2). In several
previous reports, depending on the antibodies used, one or two
species of EBNA-LP (around 31 and 37 kDa) have been detected
in Daudi cells, both lacking the Y1Y2 domain [87–90]. Here we
used the 4D3 antibody and observed the 37 kDa isoform (Figure
S1, lane 4), which corresponds to a 4-repeat species, as
determined by comparison with the EBNA-LPs expressed in
B95-8 and in 293 cells transiently transfected with plasmids
coding for 3- or 7- repeat EBNA-LP as standards (Figure S1,
lanes 1, 2 and 3). P3HR1 cl.16 cells have been reported to
express Y1Y2-deleted EBNA-LP species migrating as a major
band of around 28–30 kDa and a minor band of about 48–
50 kDa on a SDS-PAGE [91] and this was confirmed by our
western blot analysis with the 4D3 antibody (Figure S2, lane 4).
We identified these species as containing 3 and 6 W repeats,
respectively (by comparison with B95-8). In both cell lines these
truncated EBNA-LP proteins are type 2, since they were detected
with the 4D3 antibody, which detects both type 1 and type 2
EBNA-LP [89], but not with the JF186 antibody, which is type 1-
specific [92]. In the stable cell lines expressing ER-EBNA-2
proteins several EBNA-LP isoforms were detected, with 2 to 4
repeats in Daudi:ER-EBNA-2 T1/T2 (Figure S1, lanes 5 to 8)
and with 2 to 7 repeats in P3HR1 cl.16:ER-EBNA-2 T1/T2
(Figure S2, lanes 5 to 8). These species are type 1, since they can
be detected with the JF186 antibody, and are expressed from the
plasmids that code for the ER-EBNA-2 proteins (p554-4 and its
type 2 derivative [26,86]). In fact, these vectors contain not only
the ER-EBNA-2 open reading frame, but also 2 W repeats and
the Y fragment, both of type 1 sequence. The expression of
EBNA-LP species that are larger in size than that predicted
simply from the number of W fragments has been already
reported by others [92-94] and may indicate splicing of RNA
transcribed more than once around the plasmid. In both systems
(Daudi and P3HR1 cl.16:ER-EBNA-2 T1/T2) several isoforms
of full-length type 1 EBNA-LP are present but no full-length type
2 EBNA-LP is available.
To exclude the possibility that type 1 EBNA-LP proteins are
able to enhance the ability of type 1 ER-EBNA-2 to induce LMP-1
but not that of the type 2 ER-EBNA-2, we performed an assay for
EBNA-LP function, similar to that used in earlier studies [17,29], Figure 1. LMP-1 and CXCR7 are differentially induced by type 1
and type 2 EBNA-2 in Daudi:ER-EBNA-2 T1/T2 and P3HR1
cl.16:ER-EBNA-2 T1/T2 stable cell lines. (A)( B)( C)2 0 610
6 Daudi
cells stably expressing type 1 (T1) or type 2 (T2) ER-EBNA-2 were
induced with 1 mM oestrogen (+) or ethanol (-) as a solvent control, for
8, 20 or 48 hours. (A) RPA for LMP-1 mRNA. 20 mg of total cell RNA were
used. The doublet protected fragment of around 175 nt, is marked by
arrows. M: size marker, the 179 nt band is shown; P: undigested probe;
Y: yeast RNA (RPAIIIkit, Ambion). 1 representative experiment of 3 is
shown. (B) and (C) LMP-1 and CXCR7 mRNA qRT-PCR analysis. 1 mgo f
total cell RNA was used to synthesize cDNA and qPCR was performed to
quantify LMP-1 and CXCR7 transcripts. For LMP-1 qRT-PCR, values for
each sample are expressed as the ratio LMP-1/GAPDH mRNA relative to
the sample T1 stimulated with oestrogen for 20 hours, whereas for
CXCR7 qRT-PCR values shown represent the ratio between CXCR7 and
GAPDH mRNA levels, relative to the sample T1 stimulated with
oestrogen for 48 hours. Each time-point corresponds to the average
from 2 independent experiments both performed in duplicate. Error
bars represent standard errors. Data shown in panels (B) and (C) and
results presented in panel (A) are from different experiments. (D) P3HR1
cl.16 cells stably expressing type 1 (T1) or type 2 (T2) ER-EBNA-2 were
induced with 1 mM oestrogen (+) or ethanol (-) as a solvent control, for
4, 8, 12, 20, 24 or 48 hours. At these time-points proteins were extracted
and analyzed by western blotting for EBNA-2 (PE2 antibody), LMP-1 (CS
1-4 antibody) and b-actin, as a loading control. h p.i.: hours post-
induction; est: oestrogen.
doi:10.1371/journal.ppat.1002164.g001
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LMP-1 from the resident EBV genome can be examined. This
assay was adapted to compare the cooperative effect of type 1 and
type 2 EBNA-LP on type 1 and type 2 EBNA-2-induced
expression of LMP-1 in Daudi cells. Transfection of vectors
expressing type 1 or type 2 EBNA-2 alone did not produce any
significant induction of LMP-1, despite the strong expression of
both types of EBNA-2 proteins, as assessed by immunoblotting
(Figure 2). Likewise, no LMP-1 was detected when plasmids
coding for either type 1 or type 2 EBNA-LP bearing 3 repeats
were transfected, even though both EBNA-LP species were clearly
detected on a western blot as an approximately 30 kDa band. Co-
transfection of type 1 EBNA-2 and type 1 EBNA-LP plasmids
produced a clear induction of LMP-1 protein. A similar, but
slightly lower level of induction was observed when the type 2
EBNA-LP was co-expressed with type 1 EBNA-2. In contrast, up-
regulation of LMP-1 induced by the type 2 EBNA-2, in the
presence of either type of EBNA-LP, was very modest and equal
with either type 1 or type 2 EBNA-LP (Figure 2). These results
indicate that the weaker LMP-1 up-regulation induced by type 2
EBNA-2 can be ascribed to the EBNA-2 type and is not affected
by the type of EBNA-LP present. Type 1 EBNA-2 up-regulates
LMP-1 better than type 2 EBNA-2, in the presence of either type 1
or type 2 EBNA-LP. These observations support the conclusion
that, in the Daudi and P3HR1 cl.16:ER-EBNA-2 T1/T2 cell
lines, the impaired ability of type 2 EBNA-2 to induce LMP-1 is
not due to sub-optimal cooperation with the full-length type 1
EBNA-LP isoforms present in the systems, but is rather due to the
type 2 EBNA-2 protein.
Differential regulation of LMP-1 and CXCR7 genes during
early stages of infection of primary B cells with BAC-
derived EBV expressing type 1 EBNA-2 or type 2 EBNA-2
Having showed, in our previous report [26] and in the present
study in assays in cell lines, that type 1 and type 2 EBNA-2
differentially regulate LMP-1 and CXCR7, we examined whether
this phenomenon occurs also during infection of primary B cells
with BAC-derived EBV recombinant viruses, expressing either
type 1 or type 2 EBNA-2. Early stages of infection were studied
since the differences in kinetics of gene regulation induced by the
two types of EBNA-2 appeared rapidly in our cell line-based
systems. Normalized amounts of the EB viruses expressing type 1
or type 2 EBNA-2 (described in Materials and Methods) were used
to infect aliquots of 2610
6 human primary B cells, purified from
peripheral blood. Samples were taken at 1, 2, 4 and 8 days post-
infection and examined by western blotting and quantitative RT-
PCR (qRT-PCR) for EBNA-2-target gene expression. Similar
amounts of type 1 and type 2 EBNA-2 proteins were expressed, as
determined by the EBNA-2 immunoblot (Figure 3 A). In type 1
EBV-infected cells, LMP-1 transcripts were detected as soon as 2
days post-infection and gradually increased thereafter reaching
typical LCL levels of expression by day 8, whereas in type 2-
infected cells LMP-1 induction was delayed, with overall lower
levels than those observed in type 1 infection (Figure 3 B). These
different kinetics of LMP-1 mRNA induction were consistently
observed in 4 independent infection experiments, although the
overall level of expression and precise timing varied slightly in
different experiments, this variability perhaps being due to
Figure 2. In a transient transfection assay in Daudi cells, the weaker induction of LMP-1 by type 2 EBNA-2, compared to the type 1
EBNA-2, is not affected by the EBNA-LP type. 2610
6 Daudi cells were transiently transfected with an array of combinations of EBNA-2-
expressing plasmids (OriP-p294) and EBNA-LP-expressing plasmids (pSNOC) of type 1 (T1) and type 2 (T2). The Neon transfection system (Invitrogen)
was used. 24 hours after transfection, cells were lysed in RIPA lysis buffer and analyzed by SDS-PAGE followed by immunoblotting for LMP-1 (CS 1-4
antibody), EBNA-2 (PE2 antibody), EBNA-LP (4D3 antibody) and b-actin (to ensure equal loading of the proteins). The pSNOC plasmids express EBNA-
LP proteins with 3 W repeats (3R). Daudi cells already express an endogenous species of EBNA-LP which bears 4 repeats and lacks the Y1Y2 domains
(4R DY1Y2). Numbers next to the EBNA-LP blot indicate protein molecular weight in kDa. 1 representative experiment of 2 is shown.
doi:10.1371/journal.ppat.1002164.g002
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perform these experiments only on a small scale, LMP-1 protein
could not be detected by western blotting at these early times after
infection.
qRT-PCR analysis for CXCR7 mRNA revealed that uninfect-
ed resting B cells (harvested at day 0) already expressed substantial
basal amounts of mRNA (Figure 3 C), an observation consistent
with other reports [76,78]. Following viral infection, CXCR7
mRNA increased up to 2 days after infection and then settled back
to the LCL level (Figure 3 C). On the other hand, in type 2
infection the mRNA for CXCR7 was consistently at about a 4-fold
lower level than in type 1 virus-infected cells (Figure 3 C). This
trend in CXCR7 mRNA levels was observed in 3 independent
experiments, with minor differences in the overall levels of
expression.
Expression of the chemokine receptor CXCR4, which shares
the ligand CXCL12/SDF-1 with CXCR7, has been shown to be
down-regulated in primary B cells upon infection by EBV [95-97].
Uninfected primary B cells were found to express high levels of
CXCR4 mRNA (Figure 3 D), in agreement with other reports
[98]. Upon viral infection, CXCR4 transcript levels were
effectively repressed in cells infected with both type 1 and type 2
EBNA-2 recombinant EB viruses (Figure 3 D).
In order to establish LCLs, serial dilutions of preparations of
EBV-BACs expressing type 1 or type 2 EBNA-2 were used to
infect primary B lymphocytes (10
6 cells) and their outgrowth was
monitored over time. As expected, type 1 EBV-BAC-infected cells
grew very rapidly, leading to LCLs within approximately 1 month
post-infection, whereas type 2 transformants were much more
difficult to expand and yielded cell lines only after approximately 4
months of culture. The growth phenotype observed with our
recombinant type 1 and type 2 EBNA-2-expressing viruses is
consistent with the growth behaviour originally reported for the
natural strains of EBV B95-8 (type 1 prototype) and AG876 (type
2 prototype) [19]. These differences in growth kinetics, which were
revealed by microscopic observation of the cells in culture, were
mirrored by the counts of proliferating cells assessed at a single
time-point after infection, for each of the cell lines originally
infected with serial dilutions of virus (Figure S3). For example, the
amount of live cells counted in type 1 LCLs originally infected
with either 1600 or 320 GRUs of viral preparation was increased
compared to the corresponding type 2 transformants by 53 and
22-fold, respectively (Figure S3). Once LCLs were established,
hygromycin selection was applied to ensure the cells contained the
BAC-EBV constructs, which bear the hygromycin-resistance gene,
and not an EBV genome that might potentially have been
endogenous at a low level in the donor B cells. The fully
established type 1 and type 2 EBNA-2 LCLs were then further
checked by examining the pattern of expression of all the EBV
latent antigens, using western blotting (Figure S4). The EBV latent
antigens examined are expressed at similar levels and display the
expected size. EBNA-LP isoforms with slightly variable number of
W repeats (from 3 to 5) were detected in type 1 and type 2 LCLs,
but this is well above the minimum required for cooperation with
EBNA-2 [17,60]. Some differences were observed in EBNA-3A
and -3C expression levels among the several clones analyzed, but
do not seem to be consistently associated with one specific type of
LCL (Figure S4).
Mapping the regions of type 1 EBNA-2 which confer
higher B cell immortalization efficiency compared to type
2 EBNA-2
We previously developed a functional assay that distinguishes
the ability of type 1 and type 2 EBNA-2 to maintain B cell
proliferation using the EREB2.5 cell line [26,86]. EREB2.5 cells
contain a P3HR1 EBV genome lacking the EBNA-2 locus and a
separate plasmid (p554-4) expressing the ER-EBNA-2 fusion
protein. Hence, EBNA-2 activity and therefore survival and
proliferation of the cells are dependent on oestrogen. In the
absence of oestrogen, EBNA-2 function is inhibited by retention of
the conditional ER-EBNA-2 protein in the cytoplasm but cell
proliferation can be rescued if an OriP plasmid expressing
constitutive type 1 EBNA-2 protein is transfected into the cells.
In this situation the wild-type type 1 EBNA-2 functionally replaces
the ER-EBNA-2 fusion protein. In contrast, if a wild-type type 2
EBNA-2-expressing OriP vector is transfected into oestrogen-
starved cells, the cells undergo growth arrest. In this assay only
type 1 but not type 2 constitutive EBNA-2 protein can provide
essential EBNA-2 functions in trans. The trans-complementation
assay was used in the present study to identify the regions of the
type 1 EBNA-2 protein that can complement the deficiency of the
type 2 protein to maintain proliferation of LCLs. For this, several
type 1/type 2 EBNA-2 chimaeras were generated (by swapping
sequences between the two types of protein) and these were tested
for their ability to sustain cell growth of oestrogen-starved
EREB2.5 cells. The complete set of chimaeras tested and the
respective growth phenotype observed in the trans-complementa-
tion assay are shown in Figure 4 B. The chimaeras were precise
swaps of EBNA-2 sequence without extraneous amino acids at the
point of fusion. OriP-p294 plasmids expressing the chimaeric or
wild-type type 1 or type 2 EBNA-2 proteins were Amaxa-
transfected into EREB2.5 cells that had been growing normally in
the presence of oestrogen. Immediately after transfection,
oestrogen was withdrawn from the culture medium and cell
proliferation was monitored over time by counting numbers of live
cells (Figure 4 C). When the C-terminal region of type 1 EBNA-2
protein spanning from the WWPP motif (codons 323–326), within
the RBP-Jk binding domain, to the end of the protein was
swapped at homologous amino acid positions into the type 2
EBNA-2 protein (chimaera 2), live cell counts were similar to those
Figure 3. Differential regulation of LMP-1 and CXCR7 genes during early stages of infection of primary B cells with BAC-derived
EBV expressing type 1 EBNA-2 or type 2 EBNA-2. Primary B cells were isolated from peripheral blood by negative selection using RosetteSep
(Stemcell Technologies). 2610
6 cells were infected with 5000 GRUs of either T1 E2 EBV-BAC (expressing type 1 EBNA-2) or T2 E2 EBV-BAC (expressing
type 2 EBNA-2) recombinant viruses. Cells were harvested at 1, 2, 4 and 8 days post-infection and processed for protein and total RNA extraction.
Uninfected cells, harvested at day 0, were included in the analysis. (A) Whole protein extracts from each well of infected cells were loaded on an SDS-
PAGE gel and subjected to western blot analysis using the anti-EBNA-2 antibody (PE2 clone). The blots were re-probed for GAPDH to show the total
amount of protein recovered from each sample. GAPDH levels at 4 and 8 days post-infection were lower in type 2-infected cells compared to type 1-
infected cells, due to faster proliferation of the latter. (B)( C) and (D) qRT-PCR analysis of total cell RNA samples using LMP-1, CXCR7 and CXCR4
specific primers. RNAs from LCLs established with T1 and T2 EBNA-2 EBV-BAC were included in the analysis (LCL T1 E2 and LCL T2 E2). For LMP-1 qRT-
PCR (B), values for each sample are expressed as the ratio LMP-1/GAPDH mRNA relative to the sample T1 day 8; for CXCR7 qRT-PCR (C), values shown
represent the ratio between CXCR7 and GAPDH mRNA levels relative to the sample T1 day 1; for CXCR4 qRT-PCR (D), values are reported as the ratio
CXCR4/GAPDH mRNA relative to mock infected cells. The qRT-PCR experiment was performed in duplicate and error bars represent standard errors. 1
representative experiment of 4 is shown. p.i.: post-infection.
doi:10.1371/journal.ppat.1002164.g003
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assay (Figure 4 C). However, a null growth phenotype, similar to
wild-type type 2 or empty vector control, was observed with the
converse chimaera (chimaera 1), generated by joining together the
type 1 sequence from codon 1 to the WWPP motif with type 2
sequences spanning from the WWPP motif to the last codon of the
protein (Figure 4 C). Therefore, the C-terminus of type 1 EBNA-2
is able to confer a type 1 growth phenotype to type 2 EBNA-2 in
the EREB2.5 trans-complementation assay. The C-terminus of the
EBNA-2 protein includes the RG motif, the conserved region 7
(CR7), the transactivation domain (TAD) and the nuclear
localization signal (NLS) (Figure 4 A). To further map the
minimum type 1 sequences within the C-terminus of EBNA-2
responsible for the higher B cell immortalization efficiency,
additional chimaeras were constructed by swapping different
combinations of the RG, CR7, TAD and NLS regions from the
type 1 into the type 2 protein (chimaeras 3 to 7). Only when the
type 2 RG, CR7 and TAD regions were together replaced with
homologous type 1 sequences (chimaera 7), accumulation of
proliferating cells was restored to almost wild-type type 1 levels
(Figure 4 C). In contrast, chimaeras from 3 to 6 behaved like wild-
type type 2 EBNA-2, as they were unable to sustain proliferation
(Figure 4 C). Long-term culture of oestrogen-independent
EREB2.5 cells expressing the different EBNA-2 chimaeras and
wild-type proteins resulted in establishment of continuously
proliferating LCLs only in the case of chimaeras 2 and 7 and
wild-type type 1 EBNA-2. These results demonstrate that, within
the C-terminus of the type 1 EBNA-2, the RG, CR7 and TAD are
the minimum type 1 sequences required to complement the lack of
ability of type 2 EBNA-2 to rescue growth of oestrogen-depleted
EREB2.5 cells.
To ensure that the lack of growth of oestrogen-depleted
EREB2.5 cells was not due to either lack of expression or
inappropriate protein localization of the chimaeras, western blot
and immunofluorescence experiments were performed. Western
blot analysis for EBNA-2 on extracts from transfected EREB2.5
cells grown without oestrogen revealed that all the chimaeric
proteins display the expected size and are expressed at equal levels,
similar to wild-type type 1 and type 2 EBNA-2 proteins (Figure 4
D). Levels of EBNA-2 expressed from the OriP plasmids was
similar to those normally found in LCLs (Figure 4 D). For the
analysis, the PE2 antibody was used, which was previously shown
to detect the type 1 and the type 2 EBNA-2 with equal efficiency
on a western blot [26]. Immunofluorescence analysis of HeLa cells
transiently transfected with OriP-p294 plasmids, expressing the
chimaeric and wild-type EBNA-2 proteins, confirmed that all the
chimaeras are appropriately localized to the nucleus of the cells
with exclusion from nucleoli (Figure S5A), with a pattern similar to
that of wild-type type 1 and type 2 EBNA-2 (Figure S5B and [99]).
Expression of the EBNA-2-direct viral target and major EBV
oncogene LMP-1 was assessed in the EREB2.5 growth assay.
Western blot analysis revealed that at 3 and 5 days after
transfection, in oestrogen-starved cells expressing type 1 EBNA-2
and chimaeras 2 and 7, LMP-1 protein expression was maintained
at levels similar to those detected in EREB2.5 cells normally grown
in the presence of oestrogen (Figure 5 A). In contrast, LMP-1
expression was lost in type 2 EBNA-2 or empty vector-transfected
cells (Figure 5 A). qRT-PCR analysis for the mRNA of the cell
gene CXCR7 showed increased levels following expression of
either type 1 EBNA-2 or chimaeras 2 and 7, with a 14-fold
increase (type 1 EBNA-2) or approximately 7-fold increase
(chimaeras 2 and 7), compared to non-transfected cells, at 1 week
after transfection (Figure 5 B). In contrast, when type 2 EBNA-2-
expressing vector was transfected, CXCR7 mRNA was main-
tained at the same levels normally observed in non-transfected
cells (fold-increase of 1) up to 5 days after transfection but after this
time-point it was not further induced and the cells died (Figure 5
B). These results demonstrate that LMP-1 protein and CXCR7
mRNA expression levels, induced by type 1 and type 2 EBNA-2
and chimaeras 2 and 7, correlate with the growth phenotype in the
EREB2.5 trans-complementation system. Loss of LMP-1 and
CXCR7 expression in type 2 EBNA-2-expressing cells is rapidly
followed by growth arrest of the cells, whereas in cells expressing
type 1 EBNA-2, chimaera 2 or 7, maintenance of LMP-1 and
CXCR7 expression is accompanied by sustained proliferation of
the cells. Therefore the C-terminus of type 1 EBNA-2 in
chimaeras 2 and 7 is sufficient to confer induction of type 1
growth phenotype and approximately type 1 expression levels of
LMP-1 and CXCR7.
Functional differences between EBNA-2 types, mapped
to the C-terminus, are typical of type sequence
In our mapping analysis performed to identify the type 1 regions
of EBNA-2 important for B cell growth, EBNA-2 sequences from
the EBV strains B95-8 (type 1 prototype) and AG876 (type 2
prototype) were used. To ensure that the functional differences
being mapped are typical of EBV type sequences, the C-terminus
complements the deficiency of type 2 EBNA-2 in the EREB2.5 growth assay. RG, CR7 and TAD domains are the minimum type 1 sequences required.
(A) Structure of EBNA-2 protein. Type 1 EBNA-2 protein of the prototype B95-8 strain is 487 amino acids long, whereas the type 2 protein from the
strain AG876 comprises 455 amino acids. The two types of EBNA-2 proteins share around 50% of sequence identity, which consists mainly of 9 short
stretches of homology, named conserved regions (CR1 - CR9). Characteristic parts of the EBNA-2 protein are: two N-terminal self-association domains
(SAD1 and SAD2); a poly-proline region (PPR); a diversity region, a sequence with low similarity between EBV types; a region interacting with the cell
DNA-binding protein RBP-Jk (RBP-Jk); a short sequence rich in arginine and glycine residues (RG); a transactivation domain (TAD); a carboxyl-terminal
nuclear localisation signal (NLS). EBNA-LP indicates regions involved in cooperation between EBNA-2 and EBNA-LP in transcriptional activation. (B)
Panel of chimaeric proteins (C1 - C7) tested for their ability to rescue proliferation of oestrogen-starved EREB2.5 cells. The growth phenotype was
scored as ‘‘++’’ (type 1 and chimaera 2) and ‘‘+’’ (chimaera 7), when cell proliferation was maintained over time after transfection and oestrogen
withdrawal and LCLs were successfully established, or as ‘‘–’’ (type 2, chimaeras 1, 3, 4, 5 and 6), when proliferation ceased after transfection. (C) Live
cell counts of EREB2.5 cells expressing wild-type type 1/type 2 or chimaeric EBNA-2 proteins. EREB2.5 cells were transfected with OriP-p294 plasmids
expressing wild-type type 1 (T1), type 2 (T2) EBNA-2, chimaeras 1 to 7 (C1 - C7) or with empty vector (e.v.). Oestrogen was removed from the culture
medium and accumulation of proliferating cells was assessed at 1, 2, 3 and 4 weeks after transfection by counting cells that exclude Trypan Blue on a
haemocytometer. Data from 1 representative experiment of at least 4 is shown. Transfections were performed in duplicate and for each replica,
triplicate wells of cells were counted. Error bars indicate standard deviations. (D) Western blot analysis of protein extracts from EREB2.5 cells
transfected with wild-type type 1 (E2T1) and type 2 (E2T2) and chimaeric (C1 - C7) EBNA-2 proteins. Cells were harvested 4 days after transfection.
EBNA-2 was detected using the PE2 antibody, which recognizes both types. All the chimaeric EBNA-2 proteins were expressed at levels comparable to
wild-type type 1 and type 2 and displayed the expected size, which corresponds to 85 kDa (similar to type 1) for chimaera 1 and to 75 kDa (similar to
type 2) for all the other chimaeras. ER-EBNA-2 fusion protein (120 kDa) is also detected in every transfection. Triplicate samples were analyzed for
each transfection. B95-8 and AG876: positive controls for expression of EBNA-2 type 1 (85 kDa) and type 2 (75 kDa), respectively; E2.5 + est: non-
transfected EREB2.5 cells normally grown in medium supplemented with oestrogen. Immunoblotting for b-actin was performed as a loading control.
doi:10.1371/journal.ppat.1002164.g004
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sequenced and compared to the prototypes B95-8 and AG876.
The EBV strains chosen for the analysis were derived from
laboratory LCL, BL and NPC cell lines (Table 1). Comparison of
type 1 isolates to the type 1 strain of reference B95-8 showed that,
in the region examined, there is a very high percentage of identity
(. 98%) with only a few nucleotide sequence variations detected.
Most of the changes are silent but a few produce a change in the
amino acid coded. Changes in the amino acid sequence were
almost always located outside the known EBNA-2 functional
domains; only in 2 strains (Mak 1 and MABA, Table 1) were there
changes within a functional domain (TAD and NLS respectively).
Similarly, alignment of the sequence coding for the C-terminus of
EBNA-2 from several type 2 isolates against the prototype strain
AG876, indicated that the sequence identity is almost 100%, with
only 2 strains (Alouek and Wewak, Table 1) displaying nucleotide
variations (2 silent and 1 non-silent, but localized outside
functional domains). These results indicate that the functional
differences between type 1 and type 2 EBNA-2, which we have
mapped to this region, are representative of viral type sequence.
Cooperation between type 1 or type 2 EBNA-2 and
EBNA-LP in the EREB2.5 growth system
EBNA-2-mediated activation of both cell (cyclin D2) and viral
promoters (LMP-1/LMP-2B and Cp) can be greatly augmented
Figure 5. LMP-1 and CXCR7 expression induced by type 1 and type 2 EBNA-2 and chimaeras 2 and 7 correlates with the growth
phenotype in the EREB2.5 growth assay. 6610
6 EREB2.5 cells were transfected with OriP-p294 plasmids expressing type 1 EBNA-2 (E2T1), type 2
EBNA-2 (E2T1), chimaera 2 (C2) and chimaera 7 (C7) or with an empty vector (e.v.) and grown in the absence of oestrogen. At 3, 5 (A) and 7 (B) days
after transfection (T), cells were harvested and lysed in either RIPA lysis buffer to extract proteins (A) or in Trizol (Invitrogen), to extract total RNA (B).
(A) Protein samples were subjected to western blot analysis, probing for EBNA-2 (PE2 antibody), LMP-1 (CS 1-4 antibody) and b-actin, as loading
control. Constitutive EBNA-2 proteins, wild-type type 1 (85 kDa), type 2 and chimaeric (75 kDa), as well as the conditional ER-EBNA-2 (120 kDa) are
detected with the PE2 antibody. Numbers alongside the EBNA-2 immunoblot panel represent the apparent molecular weight (in kDa). (B) Total cell
RNA samples were retro-transcribed into cDNA and analyzed by qPCR to quantify the levels of CXCR7 transcripts. No RNA could be extracted from
type 2 EBNA-2-transfected cells at the day 7 time-point, since the majority of the cells were dead (. 70% relative to type 1 EBNA-2-transfected cells).
The histograms show, for each transfection, the ratio CXCR7/GAPDH mRNA relative to non-transfected EREB2.5 cells grown in the presence of
oestrogen. The analysis was performed in duplicate. Error bars represent standard errors. Data from 1 representative experiment of 2 is shown.
doi:10.1371/journal.ppat.1002164.g005
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been shown to be required for optimal virus-induced B cell
transformation [9,27–29]. Several EBNA-LP proteins, of different
type and size, are believed to be present in the EREB2.5 trans-
complementation system. To address whether these EBNA-LP
species may influence the growth phenotype induced by the wild-
type (type 1 and type 2) and chimaeric EBNA-2 proteins in
oestrogen-starved EREB2.5 cells we first determined which
specific EBNA-LP isoforms are expressed in the EREB2.5 cell
line and in the derivative oestrogen-independent LCLs established
with type 1 EBNA-2 and chimaeras 2 and 7 (Figure 6). For this,
western blot analysis was performed comparing two anti-EBNA-
LP antibodies: JF186 (type 1-specific) and 4D3, which recognizes
both types of EBNA-LP [89,92]. Using the 4D3 antibody, a type 2
EBNA-LP species of around 52 kDa was detected in non-
transfected EREB2.5 cells, normally grown in oestrogen-supple-
mented medium (Figure 6 A, lane EREB2.5 + est), and in all the
oestrogen-autonomous LCLs (Figure 6 A and B). This isoform is
encoded by the resident P3HR1 genome and is known to lack the
Y1 and Y2 domains [100]. Both antibodies detected a type 1
EBNA-LP isoform containing 3 W repeats, as determined by
comparison with lysates from 293 cells transiently transfected with
a plasmid expressing 3-repeat EBNA-LP (Figure 6 A, lane
T1ELP3R). This EBNA-LP is encoded by the endogenous plasmid
p554-4 and it was detected not only in non-transfected oestrogen-
dependent EREB2.5 cells (Figure 6 A, lane EREB2.5 + est), but
also in all the oestrogen-independent LCLs established by
transfecting chimaeras 2 and 7 or type 1 EBNA-2, analyzed over
a period of 6 and 3 months (Figure 6 A and B, respectively). This
observation suggests that in these experiments the p554-4 plasmid
is not completely lost from the oestrogen-free LCLs. This was
corroborated by the EBNA-2 immunoblot that showed continuous
expression of ER-EBNA-2 over time, although at variable levels. It
is likely that some of the p554-4 plasmid has become integrated in
these cells since, after extraction of low molecular weight DNA
from the oestrogen-independent LCLs, only the OriP-p294
plasmid (expressing constitutive EBNA-2 proteins) but not the
p554-4 vector was rescued (data not shown).
Since only a type 1 full-length EBNA-LP is present in the
EREB2.5 assay, it might be that a type-specific cooperation
between EBNA-2 and EBNA-LP would be important for optimal
proliferation in the EREB2.5 growth system and that the lack of a
full-length type 2 EBNA-LP species could hamper the growth-
promoting abilities of type 2 EBNA-2. We tested this issue directly
by transfecting plasmids expressing either type 1 or type 2 EBNA-
2 into EREB2.5 cells, in the presence or absence of a plasmid
expressing a 3-repeat type 2 EBNA-LP, to check whether the
presence of a full-length type 2 EBNA-LP (homologous to the
endogenous type 1 3-repeat EBNA-LP) would allow the type 2
EBNA-2 to sustain cell proliferation in an oestrogen-independent
fashion (Figure 7). Accumulation of proliferating cells was assessed
each week after transfection and oestrogen withdrawal over a
period of 3 weeks (Figure 7 A). Cells expressing type 1 or type 2
EBNA-2 alone displayed proliferation levels similar to those
observed in Figure 4 C. Addition of the type 2 EBNA-LP did not
produce any significant effect on growth of either type 1 or type 2
EBNA-2-expressing cells or control cells. There were no significant
differences in the levels of EBNA-2 proteins comparing the type 1
and type 2 forms, as assessed by western blotting with the PE2
antibody (Figure 7 B). Immunoblotting with the 4D3 antibody
confirmed good expression of the type 2 3-repeat EBNA-LP from
the transfected pSNOC vector. This EBNA-LP isoform displays a
slightly higher molecular weight on SDS-PAGE compared to the
endogenous type 1 3-repeat EBNA-LP (Figure 7 B) because of the
Table 1. Sequence analysis of the C-terminus of EBNA-2 from type 1 and type 2 EBV isolates obtained from laboratory LCL, BL and
NPC cell lines.

















JAC-B2 1 100% ,76% 0 0 0
Akata 1 99.8% ,76% 1 0 0
Raji 1 99.8% ,76% 1 0 0
C2+Obaji 1 98.8% ,76% 3 3 0
C666.1 1 99% ,76% 3 2 0
Mak 1 1 98.6% ,76% 3 3 1 (Ala452Thr, within TAD
3)
MABA 1 99.2% ,76% 2 1 1 (Pro478Ser, within NLS
4)
SI-B1 1 100% ,76% 0 0 0
AF-B1 2 ,76% 100% 0 0 0
WEI-B1 2 ,76% 100% 0 0 0
Alouek 2 ,76% 99.8% 1 0 0
C2+BL16 2 ,76% 100% 0 0 0
Jijoye 2 ,76% 100% 0 0 0
Wewak 2 ,76% 99.6% 1 1 0
The laboratory cell lines analysed include: LCLs (B95-8, JAC-B2, C2+Obaji, MABA, AF-B1, WEI-B1, Aloueck, C2+BL16), one NPC (C666.1) and BLs (Akata, Raji, Mak 1, SI-B1,
AG876, Jijoye, Wewak).
1Genbank accession number AJ507799;
2Genbank accession number DQ279927;
3TAD: transactivation domain;
4NLS: nuclear localization signal.
doi:10.1371/journal.ppat.1002164.t001
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sequences between type 1 and type 2 EBNA-LPs. This experiment
demonstrates that the inability of type 2 EBNA-2 to rescue growth
of oestrogen-depleted EREB2.5 cells is not due to the absence of a
full-length type 2 EBNA-LP in the system.
Discussion
The most striking biological difference between type 1 and type
2 EBV is that type 1 strains are far better than type 2 at inducing
primary B lymphocyte transformation in vitro and the EBNA-2
gene is the key determinant of this difference [5,19]. Following
EBV infection of naı ¨ve B cells in vitro, EBNA-2 drives B cell
transformation into LCLs by acting as a potent transcriptional
activator of both viral and cell genes which in turn will then cause
survival and proliferation of the infected cells [1,23–26]. Our
results demonstrate a mechanism that can account for the superior
ability of type 1 EBV to produce LCLs. Primary B cell infection
experiments using BAC-derived recombinant EB viruses showed
that higher and more rapid induction of some EBNA-2-target
genes (which are required for continuous proliferation of EBV-
infected LCLs) by type 1 EBNA-2-expressing virus correlates with
the enhanced B cell transforming capability of this virus (Figure 3
and Figure S3). In this study we have focussed our analysis on two
genes, among all the direct target genes of EBNA-2, based on their
crucial importance in B cell proliferation in the context of EBV
infection and these are the viral oncogene LMP-1 and the cell gene
CXCR7. Among the viral EBNA-2-targets, LMP-1 is the major
EBV oncogene and is required for initiation of primary B cell
transformation in vitro [8] and also for maintenance of continuous
proliferation of EBV-LCLs [62]. Our time-course analysis of
induction of LMP-1 and CXCR7 during the initial stages of
infection with type 1 or type 2 EBNA-2 BAC-EBV, revealed that
with type 2 EBNA-2 LMP-1 induction is delayed and weaker
compared to type 1 EBV-infected cells, and CXCR7 expression
levels are not maintained consistently throughout the time-points
Figure 6. Characterization of oestrogen-independent LCLs established from EREB2.5 cells expressing chimaeras 2 and 7. EREB2.5
cells transfected with OriP-p294 plasmids coding for type 1 EBNA-2 (A) or chimaeras 2 and 7 (B) and grown in the absence of oestrogen gave rise to
continuously proliferating LCLs. Protein samples were harvested from these LCLs at each month after transfection over a period of 6 months (A)o r
after 1.5 and 3 months (B) and analyzed by western blotting. The anti-EBNA-2 antibody (PE2), detected the transfected type 1 (E2) and chimaeric
(chim E2) EBNA-2 proteins as well as the endogenous ER-EBNA-2 (ER-E2). EBNA-LP immunoblotting was performed with the antibodies JF186 (type 1-
specific) and 4D3 (recognizes both types). At any time-point analyzed, both antibodies detected a type 1 3-repeat EBNA-LP species (T1 3R), expressed
from the endogenous p554-4 plasmid, indicating that the plasmid was not lost from the cells. The number of repeats was judged by comparison to
293 cells transfected with a type 1 3-repeat EBNA-LP-expressing vector (T1ELP3R). A type 2 Y1Y2-truncated isoform of around 52 kDa (T2 DY1Y2),
expressed by the resident P3HR1 genome, was also detected by the 4D3 antibody. Numbers alongside the EBNA-LP immunoblot panel represent
protein molecular weight (in kDa). b-actin immunoblots ensure equal loading of the proteins.
doi:10.1371/journal.ppat.1002164.g006
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distinguishes between the ability of type 1 and type 2 EBNA-2 to sustain cell proliferation, regardless the type of EBNA-LP. (A)
6610
6 EREB2.5 cells were transfected with OriP-p294 plasmids expressing either type 1 (E2T1) or type 2 (E2T2) EBNA-2, or with empty vector (e.v.), in
the presence or absence of a pSNOC plasmid expressing a type 2 EBNA-LP with 3 repeats (T2 ELP). Oestrogen was removed immediately after
transfection and outgrowth of the cells was monitored over a period of 3 weeks. Transfections were performed in duplicate and for each replica,
triplicate wells of cells were counted. Error bars indicate standard deviations. (B) 4 days after transfection, proteins were extracted from the cells and
fractionated by SDS-PAGE. Western blot analysis was performed using PE2 and 4D3 antibodies in order to detect EBNA-2 and EBNA-LP respectively
and confirmed equal levels of expression. The PE2 antibody, detected the transfected type 1 (T1 E2) and type 2 (T2 E2) EBNA-2 proteins as well as the
endogenous ER-EBNA-2 (ER-E2). EBNA-LP western blot showed that empty vector-transfected cells express the 30 kDa type 1 full-length 3-repeat
EBNA-LP (T1 3R), encoded by the p554-4 plasmid, and the 52 kDa Y1Y2-truncated EBNA-LP species (T2 DY1Y2), expressed from the P3HR1 resident
genome. The full-length type 2 3-repeat EBNA-LP protein (T2 3R), expressed from the pSNOC vector, is detected on the gel at approximately the same
position of the endogenous type 1 3-repeat EBNA-LP (see main text for details). The levels of b-actin did not alter throughout the experiment.
Duplicate samples for each transfection are shown. B95-8, AG876 and T2 ELP 3R (+) lanes represent positive controls for expression of EBNA-2, type 1
and type 2, and type 2 3-repeat EBNA-LP, respectively. Numbers indicate apparent molecular weight (in kDa).
doi:10.1371/journal.ppat.1002164.g007
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a type 2 LCL is eventually established (up to 4 months after
infection, with a delay of approximately 3 months compared to
type 1 LCLs), LMP-1 and CXCR7 expression levels are similar to
those detected in type 1 LCLs (Figure 3 B and C), confirming that
those genes are essential for long-term proliferation of EBV-LCLs.
Our results indicate that the key difference in transformation
efficiency between type 1 and type 2 EBV is determined by
differences in induction of the pro-survival genes LMP-1 and
CXCR7 occurring during the early stages of infection. Differential
regulation of LMP-1 and CXCR7 by the two types of EBNA-2-
expressing viruses during infection is consistent with the results
obtained in cell line based assays. We have shown that in Daudi
and P3HR1 cl.16 cell line backgrounds, using oestrogen-regulated
EBNA-2 proteins, LMP-1 protein and CXCR7 mRNA are more
potently and rapidly induced by the type 1 EBNA-2 (Figure 1 and
[26]).
Our finding that the CXCR7 gene, together with LMP-1,
accounts for the greater transforming potential of type 1 EBV,
compared to type 2, is particularly relevant in light of the fact that
two other oncogenic viruses, Kaposi’s Sacroma-associated herpes-
virus (KSHV) and human T-lymphotropic virus type 1 (HTLV-1),
have been shown to up-regulate this gene during infection.
CXCR7 induction by HTLV-1 Tax protein has been reported to
have a pro-survival effect on HTLV-1-infected T cells and in
KSHV-infected hDMVECs induction of CXCR7 is essential for
spindle cell transformation, much as occurs with EBV-mediated B
cell transformation [78,79,101-103]. Targeting of CXCR7 may
therefore represent a common mechanism exploited by oncogenic
viruses to induce cell transformation.
CXCR7 binds to the same ligand as CXCR4 (CXCL12/SDF-
1) and has been proposed to function as a modulator of CXCR4-
mediated signalling [77,104,105]. Several reports indicate that
CXCR4 is down-regulated in primary B cells upon infection by
EBV [95–97] and this was confirmed by our qRT-PCR time-
course analysis during infection with type 1 and type 2 EBNA-2
recombinant viruses (Figure 3 D). At least five EBV latent proteins
have been found potentially to be involved in modulation of
CXCR4 expression in EBV-LCLs. Stable expression of EBNA-2
and LMP-1 in the EBV-negative BJAB cell line was shown to
induce down-regulation of CXCR4 [96]. Moreover, whole
genome microarray studies indicated that CXCR4 expression is
down-regulated by EBNA-3A and EBNA-3B in EBNA-3A and -
3B knock-out LCLs, but up-regulated by EBNA-3C in LCLs with
conditional EBNA-3C protein [106–109]. In our infection
experiments CXCR4 was effectively repressed in both type 1
and type 2 EBNA-2-virus infected cells by the day 8 time-point
(Figure 3 D). In both type 1 and type 2 infections, the kinetics of
CXCR4 regulation were almost complementary to that of LMP-1
(Figure 3 B and D), consistent with the notion that both EBNA-2
and LMP-1 contribute to but are not the only determinants of
CXCR4 regulation.
From the EBNA-2 chimaeras tested, chimaeras 2 and 7
indicated that the RG, CR7 and TAD are the minimum type 1
sequences required to confer a type 1 growth phenotype to a type
2 EBNA-2 protein in the EREB2.5 trans-complementation assay
(Figure 4 B and C). This result was quite surprising and
unexpected as most of the sequence variation between type 1
and type 2 EBNA-2 lies in the N-terminal half of the protein,
mostly in the diversity region (Figure 4 A) and not in the C-
terminus. In fact, in the C-terminus the sequence homology
between the two types of EBNA-2 proteins is 62%, whereas in the
N-terminus this is 48% and only 30% in the diversity region.
Importantly, in the EREB2.5 assay the growth phenotype
correlated with the ability of the EBNA-2 proteins to induce
LMP-1 and CXCR7 genes. Type 1 EBNA-2 and chimaeras 2 and
7 maintained high levels of expression of those genes, which in
turn drive continuous proliferation of the cells leading to LCLs
establishment (Figures 5 and 6), whereas in cells expressing type 2
EBNA-2, LMP-1 and CXCR7 were not maintained at normal
physiological levels (Figure 5). These results show that the C-
terminus of type 1 EBNA-2 protein confers the ability to give
sufficient expression levels of those genes that are essential for
EBV-LCL proliferation (LMP-1, CXCR7). In summary, the data
indicate that the mechanism that accounts for the superior ability
of type 1 EBNA-2 to promote B cell growth, compared to the type
2, is higher induction of LMP-1 and CXCR7 mediated by the C-
terminal part of the protein. Although the differential effects on
LMP-1 and CXCR7 would be sufficient to cause the reduced
transformation by type 2 EBV, we have not shown that these are
the only genes involved. Attempts to complement the deficiency in
transformation by co-transfecting LMP-1 and CXCR7 expression
plasmids in the EREB2.5 growth assay were not successful (data
not shown). However, the technical difficulty of maintaining the
correct level of all the plasmids in the cells (EBV, p554-4, LMP-1
and CXCR7 expression vectors) may well account for that result.
The TAD of EBNA-2 is a strong transcriptional activator and is
essential for EBNA-2-mediated activation of viral and cell genes
and B cell transformation, since viruses lacking this domain are
immortalization-incompetent [38,65]. The TAD mediates tran-
scriptional activation at EBNA-2-target promoters by recruiting
histone acetyltransferases [54] and several host transcription
factors [51–53]. The RG sequence is involved in protein-protein
and protein-nucleic acid interactions and is important for efficient
B cell growth transformation [44]. The RG element down-
regulates EBNA-2 activation of the LMP-1 promoter but not of
the Cp [44]. The CR7 has been shown to be dispensable for B cell
growth transformation, although is important for transcriptional
cooperation with EBNA-LP [44]. In addition to the CR7, the RG
and TAD domains have also been shown to be involved in EBNA-
2/EBNA-LP transcriptional cooperation. In fact, the TAD of
EBNA-2 has been demonstrated to be required for EBNA-LP co-
activation with EBNA-2 in the context of LMP-1-promoter
reporter assays and represents a specific binding site for EBNA-
LP, as demonstrated by in vitro binding assays [31]. Moreover, the
RG and CR7 elements are able to down-regulate the high intrinsic
transcriptional activity of EBNA-2 TAD in the context of Gal4
DNA-binding fusions, suggesting a modulatory activity of these
domains on EBNA-LP function [37]. EBNA-LP has been shown
to enhance EBNA-2-mediated transcriptional activation of both
viral and cell promoters (LMP-1/LMP-2B, Cp and cyclin D2)
[27–31]; the mechanism of cooperative function is not entirely
clear but has been proposed to involve interaction with histone
deacetylase 4 [110]. EBNA-2 and EBNA-LP proteins do not
significantly associate in lymphoblasts, as demonstrated by co-
immunoprecipitation and immunofluorescence assays in previous
studies [30,31] and it has therefore been suggested that EBNA-LP
co-activation with EBNA-2 takes place only when transient
unstable interactions are established, which would allow recruit-
ment of positive transcriptional regulators to the EBNA-2 TAD at
EBNA-2-specific promoters [31].
Our mapping studies suggest that the difference in LMP-1/
CXCR7 activation and therefore in growth phenotype observed
between type 1 and type 2 EBNA-2 is determined by different
mechanisms of transcriptional activation, mediated by the TAD of
EBNA-2 and modulated by cooperation with EBNA-LP, through
the RG, CR7 and TAD EBNA-2 elements. Our results are
consistent with the crucial roles played by the EBNA-2 TAD-
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function during the EBV-driven B cell transformation process
[28,29,38]. Ongoing additional detailed mutational analysis of the
RG, CR7 and TAD sequences may identify the amino acids that
are the key determinants of the differing abilities of type 1 and type
2 EBNA-2 to transactivate target genes, and therefore sustain B
cell growth. At the biochemical level the differences between type
1 and type 2 transcriptional activation may be determined by
differences in cell transcription factors or histone acetyltransferases
recruited by type 1 EBNA-2 TAD, compared to the type 2,
resulting in higher induction of LMP-1 and CXCR7. It is
noteworthy in this context that EBNA-2 regulation of the LMP-1
promoter occurs mainly through other cell transcription factors
such as PU.1, rather than RBP-Jk [46–49,54,63]. It will be
interesting to determine in the future whether a similar situation
exists at the CXCR7 promoter. We envisage the most likely
mechanism for the differential regulation of LMP-1 and CXCR7
compared to other EBNA-2 target genes would be that their
promoters may both require specific transcription factors that
cooperate with EBNA-2, transcription factors not required for
most EBNA-2-responsive genes. We are currently investigating the
CXCR7 promoter that is active in EBV-LCLs to test this
hypothesis.
Bearing in mind the importance of EBNA-LP for enhancement
of the ability of EBNA-2 to activate genes essential for
proliferation, such as LMP-1 [28,29], we determined which
EBNA-LP species are expressed in the EREB2.5 assay and
detected a type 1 full-length EBNA-LP and a type 2 Y1Y2-
truncated isoform (Figure 6). Even though the Y1Y2 region has
been shown to have only a modulatory effect on EBNA-LP
cooperative function [28,29], one could speculate that the type 1
full-length EBNA-LP might cooperate more efficiently with the
type 1 EBNA-2 than with the type 2 EBNA-2, thereby
determining the null growth phenotype of the latter EBNA-2
type in the assay. However, the experiment illustrated in Figure 7
clearly demonstrates that this is not the case, since even in the
presence of a full-length type 2 EBNA-LP, the inability of type 2
EBNA-2 at maintaining cell proliferation was not complemented.
Therefore the EREB2.5 growth assay functionally distinguishes
between the ability of type 1 and type 2 EBNA-2 to sustain cell
proliferation, which is likely to be enhanced by cooperation with
EBNA-LP but is not influenced by the type of EBNA-LP present
in the system. A role in protection from caspase-induced apoptosis
has been recently proposed for the Y1Y2-truncated type 2 EBNA-
LP species in BL cell lines [88], however the possible contributions
of this additional function of the EBNA-LP mutant to our
EREB2.5 growth assay have not yet been explored.
Likewise, in the Daudi and P3HR1 cl.16 systems with
oestrogen-inducible EBNA-2 proteins used to analyse the time-
course induction of LMP-1 and CXCR7 by type 1 and type 2
EBNA-2 (Figure 1), several full-length type 1 EBNA-LP isoforms
are expressed from the ER-EBNA-2-coding vectors, in addition to
the type 2 Y1Y2-truncated species, encoded by the endogenous
EBV genomes (Figures S1 and S2). Similarly to the EREB2.5
assay, it might be speculated that the absence of a full-length type
2 EBNA-LP could account for the weaker induction of LMP-1/
CXCR7 by type 2 EBNA-2. By using a functional assay for
EBNA-LP cooperative function [17,29] based on the Daudi cell
line, we demonstrated that this is not the case (Figure 2). Co-
expression of type 2 EBNA-2 with either type 1 or type 2 full-
length EBNA-LP in the Daudi cell line induced only a weak up-
regulation of the endogenous LMP-1 gene, which was markedly
lower than that observed when type 1 EBNA-2 was co-expressed
with either type 1 or type 2 EBNA-LP. Therefore the weaker
induction of LMP-1 by type 2 EBNA-2 is not affected by the
EBNA-LP type. In all our assays for EBNA-LP cooperative
function an EBNA-LP construct with 3 repeat W1W2 domains has
been used, which is above the minimum (2 repeats) required for
optimal EBNA-LP function [17,29,60].
Our infection assays are similar to the EREB2.5 system and to
the Daudi/P3HR1 cl.16:ER-EBNA-2 systems in that both the
type 1 and the type 2 EBNA-2 BAC viruses express full-length type
1 EBNA-LP species (Figure S4), containing at least 3 W1W2
repeats. Based on the results discussed before and illustrated in
Figures 2 and 7, showing that the weaker induction of LMP-1 in
Daudi and the inability to maintain long-term growth in the
EREB2.5 assay by type 2 EBNA-2 is not affected by the type of
EBNA-LP present, we can infer that the gene-expression pattern
(Figure 3) and the growth phenotype (Figure S3) induced by type 2
EBNA-2-expressing BAC virus in the infection experiments is not
affected by the absence of a type 2 EBNA-LP. Moreover, the low-
efficiency transformation phenotype produced by our type 2
EBNA-2 BAC recombinant EBV is similar to that reported for the
wild-type type 2 AG876 EBV strain virus [19].
Our finding that type 2 EBNA-2 cannot rescue proliferation of
oestrogen-starved EREB2.5 cells when expressed in trans in the
EREB2.5 assay (Figure 4 B and C) is somehow surprising, if one
considers that a type 2 EBV virus is able to eventually establish
LCLs upon infection of primary B cells, albeit with very low
efficiency (Figures 3 and S3 and [19]). This difference might be
either ascribed to the truncated EBNA-LP protein present in the
EREB2.5 assay, or, more likely, to additional factors linked to the
virus/B cell interaction occurring during the process of infection.
These events occurring during the early stages of infection might
act as compensatory mechanisms for the poor ability of type 2
EBNA-2 to induce B cell proliferation. LCL outgrowth following
initial EBV infection of naı ¨ve resting B cells is a stochastic event
whereby a few cells with the correct levels of expression of those
genes required for B cell proliferation (e.g. CXCR7, LMP-1) are
selected and clonally expanded. It seems likely that slower and
lower expression of LMP-1/CXCR7 induced by type 2 EBNA-2-
expressing virus during the initial stages of infection accounts for
the low transforming efficiency displayed by this viral type.
However, once a few cells infected with type 2 EBV eventually
express the correct levels of LMP-1/CXR7, these cells are selected
and can be amplified to give rise to an LCL. In fact, in both type 1
and type 2 established LCLs, LMP-1 and CXCR7 expression
levels were ultimately approximately similar (Figure 3 B and C and
[26]).
In this study we have identified a mechanism that accounts for a
very remarkable biological difference between type 1 and type 2
EBV, namely the poorer in vitro transforming ability of type 2
strains of EBV, compared to type 1. This mechanism consists of
lower and delayed induction of both viral (LMP-1) and host
(CXCR7) genes which are essential for continuous proliferation of




P3HR1 clone 16, Daudi and Raji are EBV-positive BL cell lines
[111-113]. B cell lines were maintained in RPMI 1640 medium
(Gibco-BRL) supplemented with 10 to 20% (v/v) heat-inactivated
foetal bovine serum (FBS, BioWhittaker) and antibiotics (100
units/ml penicillin and 100 units/ml streptomycin, Gibco-BRL).
EREB2.5 cells [86] contain a conditional EBNA-2 protein
regulated by oestrogen and were maintained in RPMI 1640
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oestradiol (Sigma). Daudi:ER-EBNA-2 T1/T2 [26] and P3HR1
cl.16:ER-EBNA-2 T1/T2 stable cell lines were grown in RPMI
1640 medium supplemented with 10% FBS, antibiotics and 400 or
500 mg/mL G418 (Calbiochem) respectively. 293 and HeLa cell
lines were grown in Dulbecco Modified Eagle Medium (DMEM,
Gibco-BRL) supplemented with 10% FBS and antibiotics. 293 cell
lines stably transfected with EBV-BAC constructs were maintained
in DMEM with 10% FBS, antibiotics and 100 mg/ml Hygromycin
B (Roche).
Plasmids
The OriP-p294 plasmids used for expression of EBNA-2, type 1
and type 2, and the EBNA-2 chimaeras, were derived from the
CMVpEBNA-1 plasmid described in [114]. The EBNA-1 coding
region of the CMVpEBNA-1 plasmid was extracted and replaced
with a multiple-cloning site (MCS) comprising HindIII, BamHI and
NotI restriction sites, generating the OriP-p294 MCS plasmid. To
generate the wild-type type 1 EBNA-2-expressing plasmid, the
region comprising one BamHI W repeat and the type 1 EBNA-2
coding region from the p554 plasmid (kind gift from Bettina
Kempkes, described in [86,115]) was cloned as a BglII – NotI
fragment into OriP-p294 MCS, between BamHI and NotI sites. To
generate the homologous vector expressing a type 2 EBNA-2, the
fragment encompassing one BamHI W repeat and the type 2
EBNA-2 sequence from the pAG1 vector (described in [26]; this is
essentially homologous to p554, but carries a type 2 EBNA-2) was
extracted by BglII – NotI digestion and cloned between BamHI and
NotI sites in the OriP-p294 MCS vector. This procedure produced
the two OriP-p294 plasmids with either type 1 or type 2 EBNA-2
sequences (OriP-p294 E2T1/T2). The expression of the EBNA-2
proteins from these plasmids is driven by the EBV Wp promoter.
Additional features of these vectors include the EBV origin of
replication, OriP, and a hygromycin-resistance gene.
To generate the EBNA-2 chimaeric sequences, two pBluescript
plasmids carrying type 1 or type 2 EBNA-2 coding sequences
between EcoRI and NotI sites, extracted from the p554 and pAG1
plasmids respectively [26,86], were used. For chimaeras 1 and 2, a
fragment spanning between two BstXI sites (one in the EBNA-2
ORF, mapping to the WWPP amino acid motif, codons 323-326,
within the RBP-Jk domain, and one in the vector backbone,
downstream NotI site) was swapped between the two constructs.
To generate chimaera 3, the region comprising the CR7, TAD
and NLS elements from type 1 EBNA-2 was Pfu-PCR amplified
using a primer with overhanging SacII (59) restriction site and the
universal T3 primer. A SacII restriction site was artificially inserted
by site-directed mutagenesis, using the QuickChange Site-directed
mutagenesis kit (Stratagene), in type 2 EBNA-2 sequence, without
altering the amino acid sequence (codons 337-338, between the
RG sequence and the CR7). The type 1 PCR amplicon was then
cloned as a SacII – NotI fragment at homologous positions in the
type 2 EBNA-2 vector. A similar strategy was used to generate
chimaera 4. Briefly, a PCR amplicon, consisting of the TAD and
the NLS sequences of type 1 EBNA-2, was generated by Pfu-DNA
polymerase PCR using an oligonucleotide carrying an overhang-
ing EcoRV (59) restriction site and the universal primer T3. This
PCR product was then cloned as an EcoRV – NotI fragment into
the pBluescript plasmid carrying type 2 EBNA-2 ORF, in which a
silent EcoRV site had been previously introduced by in vitro
mutagenesis at codons 388-389, between the CR7 and the TAD.
To produce chimaera 5, the RG sequence from type 1 EBNA-2
was amplified by PCR with Pfu DNA polymerase using primers
with overhanging BstXI (59) and SacII (39) sites and cloned between
the same restriction sites into the type 2 EBNA-2 pBluescript
plasmid, carrying the artificial SacII site. Likewise, to make the
chimaera 6 construct, the type 1 sequences encompassing the RG
and the CR7 domains were Pfu-PCR amplified with primers
bearing overhanging BstXI (59) and EcoRV (39) restriction sites, the
PCR product was BstXI – EcoRV digested and then cloned
between the same positions into the type 2 EBNA-2 pBluescript
vector with the engineered EcoRV sequence. For construction of
chimaera 7, an artificial BstBI site was inserted in the type 2
EBNA-2 pBluescript plasmid, at the end of the TAD sequence
(codons 429-430). The RG, CR7 and TAD sequences were
amplified by Pfu-PCR from the type 1 EBNA-2 vector, using
primers with overhanging BstXI (59) and BstBI (39) sites. The PCR
product was then cloned into the type 2 EBNA-2 plasmid, between
the same restriction sites. The identity of all the chimaeric EBNA-
2 sequences was screened by restriction mapping and by
sequencing (data not shown). These were subcloned as EcoRI –
NotI fragments from the pBluescript background into an
intermediate vector (pSuper backbone) bearing the BglII – NotI
region from the pAG1 vector (described above), which consists of
one BamHI W repeat and the EcoRI – NotI EBNA-2 coding
sequence. The BglII – NotI sequences, comprising the BamHI W
repeat and the chimaeric EBNA-2 ORFs, were then cloned into
the OriP-p294 MCS expression vector, between BamHI and NotI
sites. Transcription of the chimaeric EBNA-2 ORFs in these
plasmids is driven by the EBV Wp promoter, similarly to the type
1 and type 2 EBNA-2 constructs.
The pSNOC vector expressing a type 1 3-repeat EBNA-LP
coding sequence is described elsewhere [116]. Briefly, this OriP
expression plasmid contains the G418-resistance locus and the
CMV immediate early promoter and the SV-40 poly A sequences,
expressing the EBNA-LP coding sequence. To generate a
homologous type 2 3-repeat EBNA-LP-expressing plasmid, a
cDNA clone from the type 2 cell line C2+BL16 was obtained by
Pfu-PCR using oligonucleotides 59- ATG CGG CCA TGT AGG
CCC ACT T -39 and 59- TGC CCA ACC ACA GGT TCA GGC
A-39, complementary to sequences within the C1 and YH exons,
respectively, of AG876 EBV strain (coordinates 11403-11425 and
36141-36119). The amplified product was subcloned into pCR2.1-
TOPO vector (Invitrogen) via TA cloning strategy and sequenced
to verify its identity to the published AG876 EBNA-LP sequence.
The type 2 3-repeat EBNA-LP cDNA was then cloned as an EcoRI
fragment into the pSNOC empty vector.
The p554-4 plasmid, bearing the coding sequences for a type 1
ER-EBNA-2 and 2 BamHI W repeats was a kind gift from Bettina
Kempkes [86,115]. The p554-4 derivative expressing type 2 ER-
EBNA-2 is described elsewhere [26]. These two vectors were used
to generate the stable cell lines P3HR1 cl.16:ER-EBNA-2 T1/T2
(described below).
Construction and characterisation of EBNA-2 EBV-BAC
mutant
EBNA-2 in the type 1 B95-8 EBV-BAC [117] was substituted
with the type 2 EBNA-2 gene by RecA-mediated homologous
recombination. The final targeting construct used for this was
cloned between the BamHI and Psp0MI sites of pKov-Kan-DCm
p4487.1 [118] and was called p121 (Figure S6). Starting from the
type 2 EBNA-2 pBluescript plasmid (described above), type 1
upstream flanking sequences were added by cloning a HindIII –
EcoRI fragment from the p554 vector [86,115] using a HindIII site
in the Bluescript polylinker. Type 1 downstream flanking sequence
was then added by substituting in a PmeIt oNotI fragment from
p554. An XhoI site in the pBluescript polylinker upstream of the
HindIII site was converted into a BglII site using an oligonucleotide
adaptor and then the whole assembly was cloned as a BglII – NotI
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resulting type 2 EBNA-2 with type 1 flanking sequences contained
type 2 EBV from 36201 – 38008 of the AG876 sequence [119].
B95-8 EBV-BAC (p2089, chloramphenicol resistant) in E. Coli
strain DH10B was kindly provided by W. Hammerschmidt [117].
For clarity, the name T1 E2 EBV-BAC is used for this plasmid in
this paper. RecA recombination to produce the type 2 EBNA-2
BAC mutant used the same methods as described previously for
construction of EBER mutants [120].
The integrity of the type 2 BAC was screened at each stage of
recombination by miniprep DNA isolation, restriction digest and
pulsed field gel electrophoresis (PFGE) in order to control for any
second-site mutations that may have occurred. Substitution of the
type 1 EBNA-2 ORF with the type 2 sequence introduced an
additional EcoRI restriction site into the EBV-BAC, in front of the
starting ATG of EBNA-2 open reading frame. Digestion with this
restriction enzyme followed by PFGE analysis therefore enabled
diagnosis of correct insertion of the type 2 EBNA-2 sequence (data
not shown). EcoRI digestion revealed also that the type 2 EBNA-2
construct had lost 2 copies (out of 6) of the BamHI W repeat
compared to the parental type 1 construct. This was confirmed by
digestion with another restriction enzyme, EcoRV (data not shown)
and was the only gross rearrangement that had occurred, as the
pattern of the remaining bands was identical in the type 1 and the
type 2 EBNA-2 BAC in both EcoRI and EcoRV digestions (data
not shown). Because the number of BamHI W repeats varies
considerably in different EBV strains, from 3 to 12 [94] and
because the repeat number found in the type 2 BAC is within this
range, this deletion was not considered to be undesirable.
Establishment of 293 stable cell lines containing EBV-BAC
with type 2 EBNA-2
EBV-BAC DNA was purified using EndoFree plasmid Maxi kit
(Qiagen) and 1 mg was transfected into 293 cells with Lipofecta-
mine2000 (Invitrogen) according to the manufacturer’s instruc-
tions. Stable 293 cell clones were isolated under Hygromycin B
selection (100 mg/ml), clonal cell lines were expanded and these
were then screened for integrity of the EBV-BAC DNA by
episome rescue and restriction digestion or PCR analysis (data not
shown). A 293 clone containing the T1 E2 EBV-BAC, used to
generate the type 2 BAC, was also produced.
Virus production and titration
Infectious virus was produced from the 293 stable cell lines
containing either T1 E2 EBV-BAC (with type 1 EBNA-2) or T2
E2 EBV-BAC (with type 2 EBNA-2) by transient transfection of
BZLF1 and BALF4-expressing plasmids using Lipofectamine2000
(Invitrogen) [117,121,122]. After 4 days, the virus-containing
supernatants were harvested, filtered (0.45 mm pore size) and titred
by infecting Raji cells and counting GFP-positive cells (Green Raji
Units, GRU) on an inverted fluorescent microscope, following
treatment with 5 nM TPA (Sigma) and 5 mM sodium butyrate
(Sigma), to enhance GFP expression.
Purification of B cells and virus infections
Primary B cells were isolated from mixed-donors buffy coat
residues by negative selection using RosetteSEP Human B cell
Enrichment cocktail (Stemcell Technologies) as described by the
manufacturer’s instructions. The isolated cells were analyzed by
flow cytometry for purity using fluorescein-isothiocyanate-conju-
gated anti-CD20 antibody (Dako). 2610
6 cells were infected with
5000 GRUs of recombinant viruses and cultured in RPMI 1640
medium supplemented with 20% FBS and antibiotics. At the
desired time-points cells were harvested and processed for RNA or
protein extraction. For LCL establishment, 10
6 cells were infected
with 5-fold serial dilutions of recombinant EBVs starting with
8000 GRUs. Cells were grown initially in RPMI 1640 medium
with 20% FBS and antibiotics and every 2-3 days half the medium
was replaced. Once LCLs had grown out in large culture volumes,
the FBS level in the medium was reduced to 10% and cells were
selected in Hygromycin B (Roche) at a concentration of 150 mg/
ml for 3 weeks. After this time, hygromycin selection was
discontinued and cells were not used for experimental investiga-
tion during hygromycin selection.
Transfections
To generate P3HR1 cl.16:ER-EBNA-2 T1/T2 stable cell lines,
2610
6 cells were transfected with 4 mg of p554-4 [86,115] or
pERT2 [26] plasmids expressing ER-EBNA-2 type 1 and type 2
respectively using Neon transfection system (Invitrogen) set at
1300 V, 30 pulse width, 1 pulse. 24 hours after transfection G418
(Calbiochem) selection was added at a concentration of 500 mg/
ml. Selected cell lines were grown out and tested for expression of
ER-EBNA-2 T1/T2 by western blotting.
For EBNA-2/EBNA-LP cooperation assays in Daudi cells, the
Neon system (Invitrogen) was used to transiently transfect 2610
6
cells with 4 mg of the OriP-p294 plasmids expressing type 1 or type
2 EBNA-2 and 2.4 mg DNA of the pSNOC plasmids expressing
either type 1 or type 2 EBNA-LP. Empty vector (OriP-p294 or
pSNOC) was added to normalize the total amount of DNA
transfected (6.2 mg). Electroporation conditions were 1400 V, 30
pulse width and 1 pulse, which routinely gave approximately 40%
transfection efficiency (assessed as GFP-positive cells when
transfecting a GFP-expressing plasmid) and 80% of cell viability.
For the EREB2.5 growth assay, 6610
6 EREB2.5 cells were
transfected with 5 mg of OriP-p294 plasmids bearing type 1/type 2
EBNA-2 sequences, either wild-type or chimaeric, using the
Amaxa system (Lonza), program A-23. b-oestradiol was with-
drawn immediately after transfection in order to select for b-
oestradiol – independent lymphoblastoid cell lines. Cells were
incubated overnight in 2 ml of complete medium supplemented
with 20% FBS and antibiotics, but without b-oestradiol, in 12-well
plates. The following day each transfected sample was diluted up
to 10 ml with culture medium and plated into 5 wells of a 24-well
plate. At the desired time-points cell samples were harvested for
cell count analysis and RNA or protein extraction.
For immunofluorescence experiments, 5610
6 HeLa cells,
grown on coverslips (VWR) in 6-well dishes, were transfected
with 4 mg of OriP-p294 plasmids encoding either type 1, type 2
EBNA-2 or the chimaeric EBNA-2 proteins using Lipofecta-
mine2000 (Invitrogen) as recommended by the manufacturer’s
instructions.
RNA extraction and qRT-PCR
Total cell RNA was extracted from growing cells using Trizol
reagent (Invitrogen) and then quantified by measuring its
absorbance at 260 nm. RNA samples were digested with RQ1
RNase-free DNase (Promega). cDNA was prepared using Proto-
script M-Mulv First strand cDNA Synthesis kit (New England
Biolabs) using random primer as recommended by the manufac-
turer’s instructions. To detect the expression of the EBNA-2-
regulated genes, quantitative RT-PCR (qRT-PCR) was used with
the primer pairs listed in Table S2. qRT-PCR was performed on
an ABI 7900HT real-time PCR machine using Absolute QPCR
SYBR Green ROX Mix (Thermo Scientific). The cycling
conditions were: 95uC for 15 min, followed by 40 cycles of
15 sec at 95uC, 30 sec at 60uC and 40 sec at 72uC on a fast block.
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to ensure absence of non-specific products. Quantification of
mRNA levels was carried out using the Delta-Delta Ct method.
Results were analyzed with SDS2.3 software (Applied Biosystems).
mRNA levels for each target gene analyzed were normalized on
the housekeeping gene GAPDH used as a loading control.
RNase protection assay (RPA)
The LMP-1-specific probe for use in RPA was generated by
PCR of genomic DNA derived from Daudi cells using the
following primers, designed based on the EBV genome sequence:
forward 59-CAC TCA TAA CGA TGT ACA GC-39 (coordinates
168881 to 169000 in EBV wild-type, accession number
NC007605) and reverse 59- CAA GAA ACA CGC GTT ACT
C-39 (coordinates 169103 to 169121 in EBV wild-type, accession
number NC007605). The PCR product (241 bp) was cloned into
pCR2.1-TOPO vector and sequenced and the plasmid was then
linearized by BamHI digestion at the 59 end of the PCR product.
1 mg of the linearized plasmid was in vitro-transcribed with T7
enzyme using the MAXIscript SP6/T7 in vitro transcription kit
(Ambion), according to the manufacturer’s instructions, for
production of
32P-labelled antisense RNA probe. RPAs were
carried out using RPAIII kit (Ambion) as recommended by the
manufacturer’s instructions. Briefly, 20 mg of total cell RNA were
hybridized overnight at 42uC with 50000 cpm of the probe. As
negative control, an equivalent amount of yeast RNA was included
in a hybridization reaction. Single-stranded RNA was digested
with an RNase A/T1 mixture for 30 min at 37uC. Protected
fragments were precipitated and separated on a polyacrylamide
gel and the gel was analyzed on a phosphoimager.
Immunoblotting and antibodies
Cell samples were lysed for 15 min on ice in 2 volumes of RIPA
lysis buffer (150 mM NaCl, 1% v/v Nonidet-P40, 0.5% v/v
deoxycholic acid, 0.1% w/v SDS, 50 mM Tris/HCl, pH 8.0)
supplemented with 1 mM PMSF (Fluka) and Complete protease
inhibitors (Roche). Samples were centrifuged at 16000 g for 15
min, to pellet cell debris, and the supernatant was harvested.
Proteins were fractionated by SDS-PAGE and transferred onto a
nitrocellulose membrane. After blocking for 1 h at room-
temperature with 5% milk powder in PBS/0.1% Tween-20
(Sigma), membranes were incubated overnight at 4uC with the
primary antibody diluted in blocking buffer. The primary
antibodies used are listed in Table S1. The secondary antibodies
were horseradish peroxidise-conjugated anti-mouse (GE Health-
care) or anti-rabbit or anti-human IgG (Dako) and were used at a
dilution of 1/2000 for 1 h at room-temperature. Bound
immunocomplexes were detected by using ECL western blotting
detection reagents (Amersham).
Indirect immunofluorescence
24 hours after transfection, HeLa cells were fixed using 4%
paraformaldehyde and permeabilized with 0.25% Triton-X 100
(Sigma) in PBS. Primary anti-EBNA-2 antibody (PE2 clone) was
diluted 1/100 in blocking buffer (1% bovine serum albumin in
PBS) and cells were incubated for 45 min at room-temperature.
The coverslips were washed 3 times with PBS and TRITC-
conjugated anti-mouse secondary antibody (Sigma) was applied at
a dilution of 1/5000 in blocking buffer for 45 min at room-
temperature. After 3 washes in PBS the coverslips were mounted
in Mowiol and visualized using a Zeiss 510 Meta laser confocal
microscope.
Accession numbers
Database entries for genes mentioned in this manuscript
include: CXCR7 (RefSeq NM 020311.2), EBV type 1 (accession
number AJ507799) and EBV type 2 (accession number
DQ279927). Annotation in the EBV genome shows EBNA-2
and LMP-1 genes.
Supporting Information
Figure S1 Analysis of EBNA-LP species expressed in
Daudi cells and Daudi:ER-EBNA-2 T1/T2 stable cell
lines. Protein extracts were prepared from Daudi:ER-EBNA-2
T1/T2 stable cell lines treated with oestrogen (est) for 4 hours (+)
or left untreated (-) and from Daudi cells. Western blot analysis
was performed using anti-EBNA-2 (PE2) and anti-EBNA-LP
(JF186 and 4D3) antibodies. In Daudi cells no EBNA-2 was
detected, because of the deletion that encompasses the EBNA-2
locus and the Y1Y2 exons of EBNA-LP. No EBNA-LP was
detected with the type 1-specific JF186 antibody, confirming that
EBNA-LP in these cells is type 2. The 4D3 antibody recognized
the 37 kDa EBNA-LP species, which corresponds to a 4-repeat
isoform and lacks Y1 and Y2 domains (marked by the arrow). In
the stable cell lines bearing the ER-tagged EBNA-2 proteins,
treatment with oestrogen produced a clear increase in abundance
of the fusion proteins. This was also accompanied by a shift in the
electrophoretic mobility, which is due to phosphorylation [115].
Full-length type 1 EBNA-LP species with 2, 3 and 4 repeats (2R,
3R and 4R) were detected with both JF186 and 4D3 antibodies,
indicating that they are expressed from the p554-4 plasmid.
Lysates from B95-8 cells and 293 expressing 3 or 7-repeat EBNA-
LP type 1 (T1 ELP 3R and 7R) were used as size markers to
determine the number of repeats in EBNA-LP proteins. b-actin
immunoblotting was performed to ensure equal loading of the
proteins. Numbers on the left hand-side of the EBNA-LP
immunoblots represent molecular weight (in kDa).
(TIF)
Figure S2 Analysis of EBNA-LP species expressed in
P3HR1 cl.16 cells and P3HR1 cl.16:ER-EBNA-2 T1/T2
stable cell lines. P3HR1 cl.16:ER-EBNA-2 T1/T2 stable cell
lines were treated with oestrogen (est) for 4 hours (+) or left
untreated (-) and proteins were extracted and analyzed by western
blotting. Protein samples from untreated P3HR1 cl.16 cells were
also included in the analysis. EBNA-2 was detected with the PE2
antibody and EBNA-LP with the JF186 and 4D3 antibodies.
Similarly to Daudi cells, no EBNA-2 was detected in P3HR1 cl.16
cells, because of the deletion, and no EBNA-LP was detected with
type 1-specific JF186 antibody, confirming that EBNA-LP in these
cells is type 2. A major ,30 kDa EBNA-LP species and a minor
,50 kDa isoform were detected with the 4D3 antibody: they both
lack the carboxyl-terminal Y1Y2 region and they comprise 3 and 6
repeats (marked by arrows). In the stable cell lines bearing the ER-
conjugated EBNA-2 proteins, both JF186 and 4D3 antibodies
detected full-length type 1 EBNA-LP species with 2, 3, 4, 5, 6 and
7 repeats (2R, 3R, 4R, 5R, 6R and 7R) expressed from the p554-4
mini-EBV genome. Protein samples from B95-8 cells and 293
expressing 3 or 7-repeat EBNA-LP type 1 (T1 ELP 3R and 7R)
were used as size markers for EBNA-LP repeats number. b-actin
immunoblotting was used as protein loading control. Numbers on
the left hand-side of the EBNA-LP blots represent protein
molecular weight (in kDa).
(TIF)
Figure S3 Live cell counts of type 1 and type 2 EBV-BAC
transformants. 10
6 primary B cells were either left uninfected
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starting with 8000 GRUs of T1 or T2 E2 EBV-BAC recombinant
viruses, which express either type 1 or type 2 EBNA-2 respectively.
Infected cells were maintained in culture over time in order to
establish LCLs and 1 month after infection differences in cell
proliferation levels were assessed by counting the number of live
cells on a haemocytometer. Error bars represent standard
deviations. Data from 1 representative experiment of 2 is shown.
(TIF)
Figure S4 Validation of T1 and T2 E2 EBV-BAC LCLs.
(A) Western blot analysis of latency-associated EBV proteins in
LCLs established with type 1 (T1) and type 2 (T2) EBNA-2 (E2)
EBV-BAC viruses. There were no major differences in EBV latent
proteins expression levels between type 1 and type 2 LCLs for
most of the antigens examined. An exception is represented by
EBNA-LP, as a 3-repeat isoform was detected in the type 2 LCL,
whereas type 1 transformants expressed EBNA-LP species with 5
and 4 repeats and in one of the type 1 clone also a 3-repeat isoform
was detected. In both viruses the EBNA-LP is type 1 (detected by
JF186 antibody). Western blot analysis of an independent type 2
LCLs confirmed expression of an EBNA-LP protein with 3 repeats
(data not shown). This is consistent with the loss of 2 BamHI W
repeats, relative to the parental type 1 EBV BAC construct
(described in Materials and Methods). This variation is not likely
to affect transformation efficiency of the two types of recombinant
viruses, since EBNA-LP proteins with a number of repeats above 2
have been shown to be functionally equivalent at enhancing
EBNA-2-mediated activation of LMP-1 [17,60]. (B) Western blot
analysis of EBNA-3A and -3C in additional type 1 (T1) and type 2
(T2) LCLs. Minor variations in expression levels were detected in
EBNA-3A and -3C across all the clones examined (A) and (B),
but these do not seem to be consistently linked to one specific type
of LCL. Re-probing with anti-b-actin antibody ensured that equal
amounts of proteins were loaded on the gel.
(TIF)
Figure S5 Nuclear localization of the chimaeric EBNA-2
proteins (A) and wild-type type 1 and type 2 (B) in HeLa
cells. OriP-p294 plasmids either bearing chimaeric EBNA-2
sequences (chimaera 1 to 7, panel A) or expressing type 1 (E2T1)
or type 2 (E2T2) EBNA-2 (panel B) were transiently transfected
into HeLa cells. After 24 hours, cells were fixed, permeabilized
and probed with the anti-EBNA-2 antibody (PE2 clone) followed
by TRITC-conjugated anti-mouse secondary antibody. The
location of the EBNA-2 proteins was assessed by confocal
microscopy. All the chimaeric EBNA-2 proteins were localized
to the nucleus, with exclusion from nucleoli, as seen for wild-type
type 1 and type 2. e.v.: empty vector-transfected cells; n.t.: non-
transfected cells; E2T1 + II Ab: cells transfected with type 1
EBNA-2-expressing plasmid and stained with the secondary
antibody only.
(TIF)
Figure S6 Schematic of the EBV sequences used to
generate the type 2 EBNA-2 BAC mutant. The boxed region
shows the part of the EBV genome cloned into the targeting vector
p121 with the EBV type sequence indicated below. The filled box
marks the EBNA-2 coding region.
(TIF)
Table S1 Primary antibodies for immunoblotting.
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